Reports Q1 revenue $730.8M, consensus $475.01M. “We entered 2026 with clear priorities-stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta’s (SRPT) next era. In the first quarter, we made meaningful progress against each,” said Doug Ingram, chief executive officer, Sarepta Therapeutics. “Our commercial portfolio has begun to stabilize, supported by expanded field engagement and a growing body of evidence reinforcing the disease-modifying impact of ELEVIDYS, which we believe is positioned to return to growth. At the same time, we are advancing Cohort 8 of the ENDEAVOR study with sirolimus pretreatment to serve our goal of once again making ELEVIDYS available to the non-ambulatory community. Finally, we remain in a position of financial strength, with positive earnings, and continued cash flow generation that enables us to fully fund our pipeline. Our potentially best-in-class clinical-stage siRNA portfolio continues to advance, with encouraging early signals in DM1 and FSHD and multiple upcoming readouts across high-value programs.”
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- SRPT Upcoming Earnings Report: What to Expect?
- Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
- Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
- Sarepta price target raised to $19 from $18 at RBC Capital